Drug Approval | July 01, 2022
Lupin receives approval from USFDA for Paliperidone extended-release tablets
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
National Institute of Biologicals should undertake the testing of more biologicals and also extend its testing expertise in helping other countries
It is a two dose vaccine to be administered intramuscularly at 28 days apart
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
We must try to make the health care system more accessible for people with disabilities
A newly revealed mechanism by Weizmann Institute of Science of ketamine’s action on potassium channels in neurons may lead to improved therapies for depression
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Subscribe To Our Newsletter & Stay Updated
